| Regulatory CD4+ CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer EY Woo, CS Chu, TJ Goletz, K Schlienger, H Yeh, G Coukos, SC Rubin, ... Cancer research 61 (12), 4766-4772, 2001 | 1609 | 2001 |
| gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand WW Overwijk, A Tsung, KR Irvine, MR Parkhurst, TJ Goletz, K Tsung, ... The Journal of experimental medicine 188 (2), 277-286, 1998 | 594 | 1998 |
| Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses MK Joubert, M Hokom, C Eakin, L Zhou, M Deshpande, MP Baker, ... Journal of Biological Chemistry 287 (30), 25266-25279, 2012 | 295 | 2012 |
| Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine V Bronte, MW Carroll, TJ Goletz, M Wang, WW Overwijk, F Marincola, ... Proceedings of the National Academy of Sciences 94 (7), 3183-3188, 1997 | 195 | 1997 |
| Pilot trial of tumor‐specific peptide vaccination and continuous infusion interleukin‐2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter … R Dagher, LM Long, EJ Read, SF Leitman, CS Carter, M Tsokos, ... Medical and Pediatric Oncology: The Official Journal of SIOP—International …, 2002 | 179 | 2002 |
| Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein TJ Goletz, KR Klimpel, N Arora, SH Leppla, JM Keith, JA Berzofsky Proceedings of the National Academy of Sciences 94 (22), 12059-12064, 1997 | 118 | 1997 |
| Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations BS Worley, LT Van den Broeke, TJ Goletz, CD Pendleton, EM Daschbach, ... Cancer research 61 (18), 6868-6875, 2001 | 115 | 2001 |
| Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics MK Joubert, M Deshpande, J Yang, H Reynolds, C Bryson, M Fogg, ... PloS one 11 (8), e0159328, 2016 | 109 | 2016 |
| CD40 ligand/CD40 stimulation regulates the production of IFN-γ from human peripheral blood mononuclear cells in an IL-12-and/or CD28-dependent manner JF McDyer, TJ Goletz, E Thomas, CH June, RA Seder The Journal of Immunology 160 (4), 1701-1707, 1998 | 94 | 1998 |
| Delivery of antigens to the MHC class I pathway using bacterial toxins TJ Goletz, KR Klimpel, SH Leppla, JM Keith, JA Berzofsky Human immunology 54 (2), 129-136, 1997 | 92 | 1997 |
| Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics D Wullner, L Zhou, E Bramhall, A Kuck, TJ Goletz, S Swanson, ... Clinical immunology 137 (1), 5-14, 2010 | 83 | 2010 |
| Differential effects of CD40 ligand/trimer stimulation on the ability of dendritic cells to replicate and transmit HIV infection: evidence for CC-chemokine-dependent and … JF McDyer, M Dybul, TJ Goletz, AL Kinter, EK Thomas, JA Berzofsky, ... The Journal of Immunology 162 (6), 3711-3717, 1999 | 73 | 1999 |
| The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective JS Bee, TJ Goletz, JA Ragheb Journal of pharmaceutical sciences 101 (10), 3580-3585, 2012 | 59 | 2012 |
| Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics V Bi, V Jawa, MK Joubert, A Kaliyaperumal, C Eakin, K Richmond, O Pan, ... Journal of pharmaceutical sciences 102 (10), 3545-3555, 2013 | 56 | 2013 |
| A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice LA Snyder, TJ Goletz, GR Gunn, FF Shi, MC Harris, K Cochlin, ... Vaccine 24 (16), 3340-3352, 2006 | 51 | 2006 |
| Toll like receptor 3 antagonists, methods and uses JM Carton, S Chen, M Cunningham, A Das, K Duffy, JM Giles-Komar, ... US Patent 8,153,583, 2012 | 50 | 2012 |
| Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy ECC Wong, VE Maher, K Hines, J Lee, CS Carter, T Goletz, W Kopp, ... Cytotherapy 3 (1), 19-29, 2001 | 49 | 2001 |
| Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein K Klimpel, TJ Goletz, N Arora, SH Leppla, JA Berzofsky US Patent 6,592,872, 2003 | 45 | 2003 |
| Induction of dendritic cell maturation by IL-18 J Li, ML Mbow, L Sun, L Li, G Yang, DE Griswold, A Schantz, DJ Shealy, ... Cellular Immunology 227 (2), 103-108, 2004 | 44 | 2004 |
| Preclinical development of AMG 139, a human antibody specifically targeting IL‐23 K Köck, WJ Pan, JM Gow, MJ Horner, JP Gibbs, A Colbert, TJ Goletz, ... British Journal of Pharmacology 172 (1), 159-172, 2015 | 29 | 2015 |
